Numerous anti-inflammatory immunomodulatory treatments have been used to combat the proinflammatory phase of sepsis; however, these immunomodulatory agents (TNF-α, IL-1β, toll-like receptor-4, etc.)have failed in clinical trials [8,9,10]. The gene discussed is TNF; the disease is Sepsis.